Skip to content

The Effect of Shengong Liquid Fumigation and Washing Combined with Alternating Red and Blue Light Irradiation on Wound Healing of Diabetic Foot at Wagner Grade 2-4

The Effect of Shengong Liquid Fumigation and Washing Combined with Alternating Red and Blue Light Irradiation on Wound Healing of Diabetic Foot at Wagner Grade 2-4

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001993
Enrollment
Unknown
Registered
2025-10-22
Start date
2023-03-01
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Foot

Interventions

Control Group:Traditional care + Recombinant human basic fibroblast growth factor gel for external application
Red-Blue Light Group:Traditional care + Red and blue alternating light therapy
Shenghong group:Traditional care + steam therapy with Shenghong
Red-Blue Light+ Shenghong Group:Traditional care + Shenghong therapy + Red and blue alternating light therapy

Sponsors

Guangdong Provincial Hospital of Integrated Chinese and Western Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Age = 18 years, meeting the diagnostic criteria for diabetes mellitus established by the World Health Organization (WHO) in 1999; (2) Diabetic Foot Ulcers (DFUs) conform to the Wagner classification criteria grades 2-4; (3) Conscious and oriented, able to cooperate with treatment and follow-up; (4) Possess the capacity to understand, willing to participate, and able to sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Pregnant women with gestational diabetes mellitus; (2) Patients with severe organic diseases of the heart, brain, liver, kidneys, etc.; (3) Patients for whom efficacy cannot be assessed (e.g., ulcers in hard-to-observe locations) or those with incomplete clinical data; (4) Patients with treatment factors that may affect efficacy assessment (e.g., concurrent use of other ulcer-healing drugs); (5) Patients with diabetic gangrene accompanied by black edema and high risk of skin breakdown; (6) Patients who use medications or treatment regimens conflicting with this study during the treatment period.

Design outcomes

Primary

MeasureTime frame
Ulcer area reduction rate;

Secondary

MeasureTime frame
Clinical Efficacy;Ulcer Wound Scoring;Pain score;Healing time;Serum and tissue vascular endothelial growth factor, interleukin-1 levels.;

Countries

China

Contacts

Public ContactDeng Chun

Guangdong Provincial Hospital of Integrated Chinese and Western Medicine

635994201@qq.com18711187944

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026